Novartis' Brolucizumab Shows Dose Advantage Over Eylea In nAMD Trials

Prospects for Novartis' nAMD eye treatment brolucizumab rose on news the novel anti VEGF treatment met primary and key secondary endpoints in two Phase III studies compared to Eylea, using less dosing.

AMD
Novartis' Brolucizumab Met Primary Endpoints In nAMD patients In Ph III Studies Versus Aflibercept • Source: Shutterstock

More from Strategy

More from Business